Bracco Imaging S.p.A., Bayer HealthCare, and Guerbet Group to Dominate the Global Contrast Injector Market

-
A number of key players are competing against each other in order to expand their existing customer base. In 2015, the contrast injector market was dominated by Bracco Imaging S.p.A (Italy), Bayer HealthCare (Germany), and Guerbet Group (France). Other players in this market include GE Healthcare (U.S.), Medtron AG (Germany), ulrich GmbH & Co. KG (Germany), AngioDynamics (U.S.) Sino Medical- Device Technology Co., Ltd. (China), Apollo RT Co., Ltd. (China), VIVID IMAGING (China), and Nemoto Kyorindo Co., Ltd. (Japan).

Bracco Imaging S.p.A is dominating the contrast injector market in 2016. The company is engaged in the discovery, development, manufacturing, and commercialization of imaging solutions for diagnostic imaging procedures to amplify the anatomic and functional visualization of internal body organs and areas. It also provides advanced administration systems for contrast imaging products. In 2011, the company acquired Swiss Medical Care (SMC) (Switzerland), to strengthen its automated system for contrast media injectors. Similarly, in 2008 and 2001, it acquired Acist Medical System (U.S.) and E-Z-EM Canada, Inc. (Canada) respectively. Bracco Imaging S.p.A serves customers in the Americas, Europe, and the Rest of the World with an employee base of 3,400 and a portfolio of 1,800 patients. The company’s notable revenue is from the European region followed by North America and RoW. The company maintains a direct sales force to reach out to its customers. It succeeded in creating a strong foothold in the market, owing to its diversified product portfolio, wide geographic reach, and focus on acquisitions and product launch.
Bayer HealthCare is second largest player in the contrast injector market in 2016. The company deals in R&D activities along with the manufacturing and marketing of products. Bayer HealthCare has two reporting segments, namely, Pharmaceuticals and Consumer Health. The Pharmaceuticals segment deals in prescription products specifically for women’s health and cardiology and specialty therapeutics in the areas of oncology, hematology, and ophthalmology. The Consumer Health segment has three divisions: consumer care, medical care, and animal health. The medical care division comprises two business units— diabetes care and radiology. The radiology business unit offers contrast-enhanced diagnostic imaging equipment along with the necessary contrast agents. The company continuously strives to strengthen its market position in various geographies by focusing on expansion and acquisitions for its contrast media injector products. The company acquired Medrad Inc., (U.S.) in 2011; the acquisition enabled Bayer AG to leverage its injector technology. In March 2014, the company invested around USD 132.9 million (EUR 100 million) to increase the production capacity of its plant in Beijing, China. This establishment enabled the company to meet the growing demand for its products by customers in China.
Guerbet Group is third largest player in the contrast injector market in 2016. The company is mainly focused on manufacturing and commercializing medical imaging contrast agents intended for diagnostic purposes. The company provides a wide range of contrast agents for X-ray examinations, MRI, and nuclear medicine. The company strives to strengthen its market position in various geographies by focusing on approval and acquisitions for its contrast injector products. For instance, the company acquired Mallinckrodt’s Contrast Media and Delivery Systems (CMDS) business for USD 270 million. The acquisition enabled Guerbert to serve new geographies like Australia and South Africa. The company also focuses on innovation and received awards for its contrast media injector products. For instance, in 2015, the company received an award from Red Dot Design for product design and New Product Innovation Award from Frost & Sullivan. Its wide range of product offerings, extensive geographic reach, and focus on innovation are contributing to the company’s large share in the market. The company has strong presence in EMEA (Europe, the Middle East, and Africa) countries followed by North America, APAC, and LATAM.
Other players operating in this market adopted the strategy of agreements, partnerships, and acquisitions, expansions, product launches, grants, product deployment, and approvals to increase their customer base across geographies and establish a strong foothold in the market.
Related Reports:

Contrast Injector Market by Product (Injector Systems (CT Injector, MRI Injector), Consumables (Injector Head, Tubing), Accessories), & Application (Radiology, Interventional Cardiology, Interventional Radiology) - Global Forecast to 2021 

Location: Northbrook, IL 60062, USA

Comments

Post a Comment

Popular posts from this blog

Minimally Invasive Surgical Instruments Market Report, 2026

-
The global minimally invasive surgical instruments market is projected to reach USD 28.9 billion by 2026 from USD 20.2 billion in 2021, at a CAGR of 7.4% during the forecast period. Growth in this market is mainly driven by factors such as the increasing number of surgical procedures worldwide, the advantages of MIS over open surgical techniques, and the increasing adoption of advanced robotics in ASCs. However, the high degree of market consolidation among market players and the requirement of high capital investments are the major factors hampering the growth of this market. Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=682 The key players in this market are Medtronic plc (Ireland), Johnson Johnson (US), Stryker Corporation (US), Abbott Laboratories, Inc. (US), Boston Scientific Corporation (US), B. Braun Melsungen AG (Germany), CONMED Corporation (US), Smith Nephew plc (UK), Zimmer Biomet Holdings, Inc. (US), Becton, Dickinson and Comp...
Read more

Advancements Fueling Cardiac Monitoring Devices Market Growth

-
The global Cardiac Monitoring and Management Devices Market has been experiencing an upward surge, projected to reach an impressive USD 26.8 billion by 2025 from its valuation of USD 22.1 billion in 2020, with a steady Compound Annual Growth Rate (CAGR) of 4.0% from 2020 to 2025. This exponential growth can be attributed to several key factors that continue to shape and propel this industry forward. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=55 Factors Driving Cardiac Monitoring Devices Market Growth Rising Cardiovascular Disease Prevalence: The prevalence of cardiovascular diseases (CVD) is on the rise globally, driving the demand for advanced cardiac monitoring devices. This trend is a significant catalyst for the market's growth trajectory. Innovative Product Launches: Market players have been proactive in introducing innovative products, leveraging advanced technologies. These advancements include improved algorithms, simplified...
Read more

Wearable Medical Device Market Growth Analysis Industry Report 2027

-
Image
The growth of the market is attributed to the technological advances in medical devices, increasing penetration of smartphones and growing number of smartphone-based healthcare apps compatible with wearable devices, and increasing awareness about physical fitness. According to research report the wearable medical devices market is expected to reach USD 32.71 billion by 2027 from USD 6.22 billion in 2017, at a CAGR of 18.3%. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=81753973 Based on type, the wearable medical devices market is segmented into activity monitors, smartwatches, smart clothing, and patches. The activity monitors segment is expected register the highest CAGR during the forecast period. The high growth of this segment can be attributed to factors such as the rising adoption of sedentary and unhealthy lifestyles, rising prevalence of lifestyle diseases, and growing awareness of health and fitness. Based on application,...
Read more